Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Nastech reacquires intranasal apomorphine rights following Pfizer-Pharmacia merger

April 23, 2003

Potential use of mozavaptan plus furosemide for treating edema and hyponatremia

April 22, 2003

Effect of vardenafil on exercise tolerance in stable angina pectoris

April 14, 2003

Long-term treatment with Fosrenol controls phosphate in end-stage renal disease

April 11, 2003

New series of PDE5 inhibitors in early development at Schering-Plough

April 11, 2003

Novel 5alpha-reductase inhibitors covered by Jenapharm patent

April 11, 2003

DA-8159 is well tolerated in healthy volunteers and without significant hemodynamic effects

April 8, 2003

Renagel receives NHI drug price listing in Japan

April 8, 2003

Sumitomo presents new muscarinic M3 antagonists for use in urinary incontinence

April 7, 2003

ACS news: inhibitors of phosphate transport for use in patients with chronic renal disease

April 2, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...